2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Gene Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3215 JADE2 is a chromatin dependency that sustains menin-KMT2A transcription in acute myeloid leukemia

Pengcheng Zhang, MD, BS, Xinyue Zhou, BS2, Zihan Zhang3, Jun Zhang4, Ravi Bhatia, MD5, Rui Lu6
1 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
2 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
6 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States

Acute myeloid leukemia (AML) driven by KMT2A rearrangements depends on aberrant transcriptional programs controlled by the Menin-KMT2A complex. Although Menin inhibitors have demonstrated clinical activity, incomplete responses and acquired resistance highlight the need to identify additional regulators of Menin-dependent transcription. Epigenetic accessory proteins may provide more selective therapeutic targets than broadly acting chromatin-modifying enzymes, but their functions in AML remain poorly defined.

 

Using a chromatin-focused CRISPR screen in a human HOXA9 reporter model, we identified JADE2, an accessory component of the KAT7 histone acetyltransferase complex, as a top regulator of KMT2A-fusion target-gene expression. JADE2 depletion reduced HOXA9 expression and broadly suppressed KMT2A-fusion transcriptional programs, including HOXA cluster genes, MEIS1, and MEF2C. Functional studies across genetically diverse AML models demonstrated that JADE2 loss preferentially impaired the proliferation of KMT2A-rearranged AML cells while having limited effects in non-KMT2A-rearranged leukemia models.

 

The requirement for JADE2 was further established in a genetically defined MLL-AF9 AML model. Jade2 depletion suppressed leukemia cell growth in vitro and reduced disease progression following transplantation, as reflected by decreased peripheral leukocytosis, splenomegaly, and bone marrow leukemia burden. Loss of Jade2 also significantly prolonged recipient survival. In contrast to disruption of the catalytic subunit KAT7, JADE2 loss did not cause broad changes in global histone acetylation and had minimal effects on nonmalignant hematopoietic progenitor models, supporting a potential therapeutic window.

 

High-density CRISPR domain scanning identified discrete regions of JADE2 required for leukemia maintenance and chromatin association. Functional rescue and chromatin-profiling studies further demonstrated that an N-terminal chromatin-recognition module is necessary for JADE2 recruitment to oncogenic target genes and for AML cell proliferation. Genome-wide chromatin profiling showed preferential localization of JADE2 at Menin-KMT2A target genes. Complementary proteomic, genetic co-dependency, and biochemical analyses identified a functional association between JADE2 and Menin. These findings support a model in which JADE2 couples chromatin recognition with Menin-dependent oncogenic transcription.

 

Together, our results establish JADE2 as a selective regulator of Menin-KMT2A transcription and a previously unrecognized dependency in KMT2A-rearranged AML. Targeting JADE2 or its chromatin-engagement mechanism may suppress leukemia-associated transcription while avoiding the broader hematopoietic toxicity associated with direct KAT7 inhibition.

 

Pengcheng Zhang, MD, BS: No relevant conflicts of interest to declare.